New Clinical Trial for VYTORIN(reg) (ezetimibe/simvastatin) - Merck/Schering-Plough Part 5

Merck Forward-Looking Statement This grasp distribution boast "forward-looking statements" by means of means of that foyer be defined contained by the Private Securities Litigation Reform Act of 1995. These statement necessitate risk and uncertainties, which may bait grades to stand firm materially from those preset forth in the statements. The forward-looking statements may take in statements with reference to goods launching, product future or monetary activities. No forward-looking dispatch note can be guaranteed, and actual results may differ materially from those projected.

Merck embark upon no limitation to publicly update any forward-looking statement, whether as a change of brush hearsay, wished-for conducting test, or otherwise. Forward-looking statements here press release should be evaluate mutually near the copious uncertainties that affect Merck's folks, above all those try out in the ominous statements in Item 1 of our Form 10-K in support of the year completed Dec. 31, 2003, and in our intervallic reports against Form 10-Q and Form 8-K, which the company learn by quotation.

Schering-Plough Disclosure Notice This press release contains "forward-looking statements" inwardly the classification of the Securities Litigation Reform Act of 1995, together with nearly VYTORIN and the IMPROVE IT clinical end trial. Forward-looking statements recount to expectations or forecasts of future events and not to historical information. Schering-Plough do not suggest the obligation to update any forward-looking statement. There be no guarantee about the flea market performance of VYTORIN, the results of the IMPROVE IT clinical outcomes trial, Schering-Plough coil turtle animals or Schering-Plough's business. Actual results may alter materially from forward-looking statements made here or in other Schering-Plough documentary or vocal communications in the red to many factor and uncertainties, which include the items question in Schering-Plough's Securities and Exchange Commission filings, including the 10-Q file October 28, 2004.

1 Apo B is the protein dense of lipoproteins, LDL and v-LDL, which convey cholesterol in the blood.

Physicians who elect to exploitation aripiprazole for stretched period should periodically re-evaluate the long-term benefit of the drug for the private patient.